Company Overview and News
Mumbai: Honda Motorcycle and Scooter India Pvt. Ltd (HMSI), the maker of Activa scooters, has been outselling erstwhile joint venture partner Hero MotoCorp Ltd in the popular executive motorcycle segment since FY15, according to data compiled by the automobile industry lobby group. Honda sold more than 980,00 units in the year ended March 2018 in the executive segment (motorcycles with engine capacities between 110cc and 125cc) compared with Hero’s 870,000 units.
BAJAJ-AUTO 500182 HEROMOTOCO 532977 HRTQY
The sharp depreciation of the rupee versus US dollar and other currencies would impact earnings of auto companies. Net exporters namely Bajaj Auto, Bharat Forge and Balkrishna Industries would be beneficiaries, while net importers such as Maruti may lose out.
BAJAJ-AUTO BALKRISIND 532977 500493 502355 BHARATFORG
Jaguar Land Rover is proving to be a drag on Tata Motors' financials, so much that N Chandrasekaran-led carmaker's market capitalisation currently is even lesser than that of two-wheeler companies Bajaj Auto and Eicher Motors.
BAJAJ-AUTO 505200 ECQRY 532977 500570 TATAMOTORS EICHERMOT TTM
Mumbai: The BSE Sensex rebounded over 100 points in opening trade Wednesday on value-buying in recently battered stocks amid strength in the rupee and positive global cues. The 30-share BSE index recovered by 142.26 points, or 0.38 per cent, to 37,432.93 in opening trade. The index had lost almost 800 points in the previous two sessions as rupee woes and trade war worries spooked investors. The NSE Nifty was up 50.
BAJAJ-AUTO 532977 BHRQY 533278 532215 500470 532187 AXISBANK 500570 BHARTIARTL TATAMOTORS CLNDY AXB INDUSINDBK IBN AXBKY 532454 AXBA ICICIBANK TTST TATASTEEL TATLY 532174 COALINDIA TTM
The Indian benchmark indices continues to trade in the red this Tuesday afternoon with the Nifty50 down 16 points and is trading at 11,361 while the Sensex is trading lower by 38 points at 37,547.
BAJAJ-AUTO INDIANB IOB 500325 UBL DABUR BRTQY 532712 DBRQY 532478 SYNDIBANK 500096 RCOM 532121 532483 SONATSOFTW 500696 500179 GAILF 500570 BRITANNIA RLNIY 504212 SBAZ AXB 532505 YYBKY CNRYY VIJAYABANK AXBA 532276 GAILY GLOBUSSPR CANBK 507458 ANDHRABANK 500825 RELIANCE 532814 532418 HINDUNILVR 532977 533155 JUBLFOOD 532215 HCL-INSYS 532388 532221 AXISBANK RIGD JBLWY TATAMOTORS UNIVCABLES YESBANK UBNC HINDALCO UBHOLDINGS 532648 UNBWY 533104 532401 AXBKY 532179 HNDNF CRPKY CORPBANK UCOBANK DENABANK 500440 TTM
Auto stocks fell up to 4.2 per cent Tuesday after domestic passenger vehicle sales declined for the second month in succession.
BAJAJ-AUTO TVSMOTOR 500877 APOLLOTYRE AYRQY 532977 MRZUY AKLD 532500 500182 532343 MARUTI HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS AKLS ASHOKLEY TTM
Prime Minister Narendra Modi's Make-in-India call has probably found more takers in the auto industry than any other, and perhaps accomplished in the mission's truest sense -- targeting global markets. Bajaj Auto, TVS Motor Company, Eicher Motors, Daimler, Volvo and General Motors have made India a production base for making vehicles and engines exclusively for the export markets.
BAJAJ-AUTO ECQRY TVSMOTOR 532977 DDAIF 505200 532343 GM EICHERMOT
Mumbai: The BSE benchmark Sensex Tuesday rose 95 points, but soon turned choppy on weak global cues amid lingering global trade war concerns. The 30-share index opened higher by 95.32 points, or 0.25 per cent, at 38,017.49. It, however, turned choppy and was trading 8 paise, or 0.02 per cent, higher at 37,930.97 at 0930hrs.
BAJAJ-AUTO AXB 532977 533278 532215 AXBKY 500182 AXBA 500470 TTST TATASTEEL TATLY AXISBANK HEROMOTOCO HRTQY 500570 TATAMOTORS CLNDY COALINDIA TTM
Mumbai: Markets remained in better form for the second straight session Friday, with the Sensex closing over 147 points higher as auto shares zoomed on sustained buying by domestic institutional investors amid the rupee staging a recovery.
BAJAJ-AUTO 500182 HEROMOTOCO 532977 HRTQY 500570 TATAMOTORS TTM
Bajaj Auto plans to produce more three-wheelers after road transport and highways minister Nitin Gadkari said auto-rickshaws running on alternative fuels will no longer need permits to ply. Bajaj Auto, which has an 86 per cent share in the three-wheeler market, intends to produce 10 lakh commercial vehicles every year that include three-wheelers and quadricycles, up from 8.4 lakh units currently. Investors will see how the company plans to expand its production line.
Bajaj Auto will add new capacity at its three-wheeler and quadricycle making plant in Aurangabad in anticipation of new demand with the end of the ‘Permit Raj’.
Mumbai: Falling for the sixth straight session, the BSE Sensex shed about 140 points Wednesday to close at an over two-week low of 38,018.31 as investor sentiment remained bearish amid a plunging rupee and weak global cues. The rupee crashed to a fresh record low of 71.96 against the US dollar in intra-day trade on the back of rising bond yields and crisis in emerging market currencies. Market sentiment was further dampened after a monthly survey showed that India’s services sector activity fell in August from July’s 21-month peak as new business orders declined.
BAJAJ-AUTO 500820 532977 BHRQY ASIANPAINT 533278 532215 500470 532187 AXISBANK HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY YESBANK AXB INDUSINDBK IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM
New Delhi: The benchmark BSE Sensex Tuesday lost about 155 points to close at an over two-week low of 38,157.92, falling for the fifth session in a row following sustained foreign fund outflows, surging global crude oil prices and tumbling rupee against dollar.
BAJAJ-AUTO 500820 532977 BHRQY ASIANPAINT TTNQY 533278 500470 532540 532187 HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY YESBANK INDUSINDBK IBN 532648 YYBKY 500182 532454 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 TCS HRTQY COALINDIA TTM
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...